Most-cited articles · 2021
The 50 most-cited articles in JAMA, 2021
Ranked by OpenAlex citation count on 29 October 2026, out of 1,622 eligible articles JAMA published in 2021. Ranks are frozen; this page will not change. Number one, with 3,988 citations: Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization.
- Cohort
- 1,622 articles
- Listed
- Top 50 (3.1%)
- Open access
- 41 of 50
- Snapshot
- 2026-10-29
The most-cited JAMA articles of 2021 cluster around several themes. Clinical reviews of cancer and other common conditions rank highly, including Diagnosis and Treatment of Metastatic Colorectal Cancer, Diagnosis and Treatment of Hip and Knee Osteoarthritis, and Pancreatic Cancer. Cancer screening recommendations from the US Preventive Services Task Force also appear near the top. The single most-cited article is Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization, with 3988 citations. Guidance on reporting race and ethnicity in journals and randomized trials of semaglutide for weight management also feature prominently.
For readers, this list offers a view of the work that drew the most citation attention in JAMA during 2021. It reflects which topics and article types other researchers cited most often, based on OpenAlex counts among 1622 eligible articles. The ranking describes citation frequency only and does not by itself indicate quality, importance, or clinical significance.
Introduction written from the titles and abstracts on this list. Every figure below is the source.
Ask about these papers
Grounded in this list only, with sources.
- 1top 0.1%
Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian Randomization
Veronika Whitesell Skrivankova, Rebecca Claire Richmond, Benjamin A. R. Woolf, James Yarmolinsky, Neil M Davies and 13 more
3,988 citationsOpen access (CC-BY)doi:10.1001/jama.2021.18236OpenAlex
Show abstractHide abstract
Importance: Mendelian randomization (MR) studies use genetic variation associated with modifiable exposures to assess their possible causal relationship with outcomes and aim to reduce potential bias from confounding and reverse causation. Objective: To develop the STROBE-MR Statement as a stand-alone extension to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guideline for the reporting of MR studies. Design, Setting, and Participants: The development of the STROBE-MR Statement followed the Enhancing the Quality and Transparency of Health Research (EQUATOR) framework guidance and used the STROBE Statement as a starting point to draft a checklist tailored to MR studies. The project was initiated in 2018 by reviewing the literature on the reporting of instrumental variable and MR studies. A group of 17 experts, including MR methodologists, MR study design users, developers of previous reporting guidelines, and journal editors, participated in a workshop in May 2019 to define the scope of the Statement and draft the checklist. The draft checklist was…
- 2top 0.2%
Diagnosis and Treatment of Metastatic Colorectal Cancer
Leah H. Biller, Deborah Schrag
2,626 citationsdoi:10.1001/jama.2021.0106OpenAlex
Show abstractHide abstract
Importance: Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide with more than 1.85 million cases and 850 000 deaths annually. Of new colorectal cancer diagnoses, 20% of patients have metastatic disease at presentation and another 25% who present with localized disease will later develop metastases. Observations: Colorectal cancer is the third most common cause of cancer mortality for men and women in the United States, with 53 200 deaths projected in 2020. Among people diagnosed with metastatic colorectal cancer, approximately 70% to 75% of patients survive beyond 1 year, 30% to 35% beyond 3 years, and fewer than 20% beyond 5 years from diagnosis. The primary treatment for unresectable metastatic CRC is systemic therapy (cytotoxic chemotherapy, biologic therapy such as antibodies to cellular growth factors, immunotherapy, and their combinations.) Clinical trials completed in the past 5 years have demonstrated that tailoring treatment to the molecular and pathologic features of the tumor improves overall survival. Genomic profiling to detect somatic…
- 3top 0.2%
Diagnosis and Treatment of Hip and Knee Osteoarthritis
Jeffrey Neil Katz, Kaetlyn R. Arant, Richard F. Loeser
2,323 citationsOpen accessdoi:10.1001/jama.2020.22171OpenAlex
Show abstractHide abstract
Importance: Osteoarthritis (OA) is the most common joint disease, affecting an estimated more than 240 million people worldwide, including an estimated more than 32 million in the US. Osteoarthritis is the most frequent reason for activity limitation in adults. This Review focuses on hip and knee OA. Observations: Osteoarthritis can involve almost any joint but typically affects the hands, knees, hips, and feet. It is characterized by pathologic changes in cartilage, bone, synovium, ligament, muscle, and periarticular fat, leading to joint dysfunction, pain, stiffness, functional limitation, and loss of valued activities, such as walking for exercise and dancing. Risk factors include age (33% of individuals older than 75 years have symptomatic and radiographic knee OA), female sex, obesity, genetics, and major joint injury. Persons with OA have more comorbidities and are more sedentary than those without OA. The reduced physical activity leads to a 20% higher age-adjusted mortality. Several physical examination findings are useful diagnostically, including bony enlargement in knee…
- 4top 0.3%
Screening for Colorectal Cancer
US Preventive Services Task Force, Karina W. Davidson, Michael J. Barry, Carol M. Mangione, Michael D. Cabana and 14 more
2,056 citationsOpen access (CC-BY)doi:10.1001/jama.2021.6238OpenAlex
Show abstractHide abstract
Importance Colorectal cancer is the third leading cause of cancer death for both men and women, with an estimated 52 980 persons in the US projected to die of colorectal cancer in 2021. Colorectal cancer is most frequently diagnosed among persons aged 65 to 74 years. It is estimated that 10.5% of new colorectal cancer cases occur in persons younger than 50 years. Incidence of colorectal cancer (specifically adenocarcinoma) in adults aged 40 to 49 years has increased by almost 15% from 2000-2002 to 2014-2016. In 2016, 26% of eligible adults in the US had never been screened for colorectal cancer and in 2018, 31% were not up to date with screening. Objective To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for colorectal cancer in adults 40 years or older. The review also examined whether these findings varied by age, sex, or race/ethnicity. In addition, as in 2016, the USPSTF commissioned a report from the Cancer Intervention and Surveillance Modeling Network Colorectal…
- 5top 0.4%
Pancreatic Cancer
Wungki Park, Akhil Chawla, Eileen Mary O'Reilly
1,903 citationsOpen accessdoi:10.1001/jama.2021.13027OpenAlex
Show abstractHide abstract
Importance: Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC is increasing by 0.5% to 1.0% per year, and it is projected to become the second-leading cause of cancer-related mortality by 2030. Observations: Effective screening is not available for PDAC, and most patients present with locally advanced (30%-35%) or metastatic (50%-55%) disease at diagnosis. A multidisciplinary management approach is recommended. Localized pancreas cancer includes resectable, borderline resectable (localized and involving major vascular structures), and locally advanced (unresectable) disease based on the degree of arterial and venous involvement by tumor, typically of the superior mesenteric vessels. For patients with resectable disease at presentation (10%-15%), surgery followed by adjuvant chemotherapy with FOLFIRINOX (fluorouracil, irinotecan, leucovorin, oxaliplatin) represents a standard therapeutic approach with an anticipated median overall survival of 54.4 months, compared with 35…
- 6top 0.4%
Screening for Lung Cancer
US Preventive Services Task Force, Alex H. Krist, Karina W. Davidson, Carol M. Mangione, Michael J. Barry and 15 more
1,815 citationsOpen accessdoi:10.1001/jama.2021.1117OpenAlex
Show abstractHide abstract
IMPORTANCE: Lung cancer is the second most common cancer and the leading cause of cancer death in the US. In 2020, an estimated 228 820 persons were diagnosed with lung cancer, and 135 720 persons died of the disease. The most important risk factor for lung cancer is smoking. Increasing age is also a risk factor for lung cancer. Lung cancer has a generally poor prognosis, with an overall 5-year survival rate of 20.5%. However, early-stage lung cancer has a better prognosis and is more amenable to treatment. OBJECTIVE: To update its 2013 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the accuracy of screening for lung cancer with low-dose computed tomography (LDCT) and on the benefits and harms of screening for lung cancer and commissioned a collaborative modeling study to provide information about the optimum age at which to begin and end screening, the optimal screening interval, and the relative benefits and harms of different screening strategies compared with modified versions of multivariate risk prediction models. POPULATION:…
- 7top 0.5%
Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals
Annette Flanagin, Tracy Frey, Stacy L. Christiansen
1,609 citationsdoi:10.1001/jama.2021.13304OpenAlex
Show abstractHide abstract
The goal of this guidance is to provide recommendations and suggestions that encourage fairness, equity, consistency, and clarity in use and reporting of race and ethnicity in medical and science journals.As previously summarized, "terminology, usage, and word choice are critically important, especially when describing people and when discussing race and ethnicity.Inclusive language supports diversity and conveys respect.Language that imparts bias toward or against persons or groups based on characteristics or demographics must be avoided." 1 With the publication of an earlier version of this guidance, 1 comments were invited, and helpful assessments and comments were received from numerous reviewers, scholars, and researchers, who provided valuable feedback and represented diverse expertise and opinions.After thorough review of these comments (some of which did not agree with others) and additional research and discussion, the guidance was revised and updated, and additional formal review was obtained.In this Editorial, we present the updated guidance, and we sincerely thank the…
- 8top 0.5%
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity
Domenica Rubino, Niclas Abrahamsson, Melanie Jane Davies, Dan Hesse, Frank L. Greenway and 25 more
1,442 citationsOpen accessdoi:10.1001/jama.2021.3224OpenAlex
Show abstractHide abstract
Importance: The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like peptide 1 receptor agonist, on weight loss maintenance in people with overweight or obesity is unknown. Objective: To compare continued once-weekly treatment with subcutaneous semaglutide, 2.4 mg, with switch to placebo for weight maintenance (both with lifestyle intervention) in adults with overweight or obesity after a 20-week run-in with subcutaneous semaglutide titrated to 2.4 mg weekly. Design, Setting, and Participants: Randomized, double-blind, 68-week phase 3a withdrawal study conducted at 73 sites in 10 countries from June 2018 to March 2020 in adults with body mass index of at least 30 (or ≥27 with ≥1 weight-related comorbidity) and without diabetes. Interventions: A total of 902 participants received once-weekly subcutaneous semaglutide during run-in. After 20 weeks (16 weeks of dose escalation; 4 weeks of maintenance dose), 803 participants (89.0%) who reached the 2.4-mg/wk semaglutide maintenance dose were randomized (2:1) to 48 weeks of continued subcutaneous semaglutide (n…
- 9top 0.6%
Diagnosis and Management of Infertility
Sandra Ann Carson, Amanda Nicole Kallen
1,293 citationsOpen accessdoi:10.1001/jama.2021.4788OpenAlex
Show abstractHide abstract
IMPORTANCE: In the US, approximately 12.7% of reproductive age women seek treatment for infertility each year. This review summarizes current evidence regarding diagnosis and treatment of infertility. OBSERVATIONS: Infertility is defined as the failure to achieve pregnancy after 12 months of regular unprotected sexual intercourse. Approximately 85% of infertile couples have an identifiable cause. The most common causes of infertility are ovulatory dysfunction, male factor infertility, and tubal disease. The remaining 15% of infertile couples have "unexplained infertility." Lifestyle and environmental factors, such as smoking and obesity, can adversely affect fertility. Ovulatory disorders account for approximately 25% of infertility diagnoses; 70% of women with anovulation have polycystic ovary syndrome. Infertility can also be a marker of an underlying chronic disease associated with infertility. Clomiphene citrate, aromatase inhibitors such as letrozole, and gonadotropins are used to induce ovulation or for ovarian stimulation during in vitro fertilization (IVF) cycles. Adverse…
- 10top 0.7%
Diagnosis and Treatment of Multiple Sclerosis
Marisa McGinley, Carolyn H. Goldschmidt, Alexander D Rae-Grant
1,202 citationsdoi:10.1001/jama.2020.26858OpenAlex
Show abstractHide abstract
Importance: Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease of the central nervous system characterized by inflammatory demyelination with axonal transection. MS affects an estimated 900 000 people in the US. MS typically presents in young adults (mean age of onset, 20-30 years) and can lead to physical disability, cognitive impairment, and decreased quality of life. This review summarizes current evidence regarding diagnosis and treatment of MS. Observations: MS typically presents in young adults aged 20 to 30 years with unilateral optic neuritis, partial myelitis, sensory disturbances, or brainstem syndromes such as internuclear ophthalmoplegia developing over several days. The prevalence of MS worldwide ranges from 5 to 300 per 100 000 people and increases at higher latitudes. Overall life expectancy is less than in the general population (75.9 vs 83.4 years), and MS more commonly affects women (female to male sex distribution of nearly 3:1). Diagnosis is made based on a combination of signs and symptoms, radiographic findings (eg, magnetic resonance…
- 11top 0.7%
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
Thomas A. Wadden, Timothy Silleck Bailey, Liana K. Billings, Melanie Jane Davies, Juan P. Frías and 8 more
1,113 citationsOpen accessdoi:10.1001/jama.2021.1831OpenAlex
Show abstractHide abstract
Importance: Weight loss improves cardiometabolic risk factors in people with overweight or obesity. Intensive lifestyle intervention and pharmacotherapy are the most effective noninvasive weight loss approaches. Objective: To compare the effects of once-weekly subcutaneous semaglutide, 2.4 mg vs placebo for weight management as an adjunct to intensive behavioral therapy with initial low-calorie diet in adults with overweight or obesity. Design, Setting, and Participants: Randomized, double-blind, parallel-group, 68-week, phase 3a study (STEP 3) conducted at 41 sites in the US from August 2018 to April 2020 in adults without diabetes (N = 611) and with either overweight (body mass index ≥27) plus at least 1 comorbidity or obesity (body mass index ≥30). Interventions: Participants were randomized (2:1) to semaglutide, 2.4 mg (n = 407) or placebo (n = 204), both combined with a low-calorie diet for the first 8 weeks and intensive behavioral therapy (ie, 30 counseling visits) during 68 weeks. Main Outcomes and Measures: The co-primary end points were percentage change in body weight and…
- 12top 0.8%
Acute Pancreatitis
Michael A. Mederos, Howard A. Reber, Mark D. Girgis
1,035 citationsdoi:10.1001/jama.2020.20317OpenAlex
Show abstractHide abstract
IMPORTANCE: In the United States, acute pancreatitis is one of the leading causes of hospital admission from gastrointestinal diseases, with approximately 300 000 emergency department visits each year. Outcomes from acute pancreatitis are influenced by risk stratification, fluid and nutritional management, and follow-up care and risk-reduction strategies, which are the subject of this review. OBSERVATIONS: MEDLINE was searched via PubMed as was the Cochrane databases for English-language studies published between January 2009 and August 2020 for current recommendations for predictive scoring tools, fluid management and nutrition, and follow-up and risk-reduction strategies for acute pancreatitis. Several scoring systems, such as the Bedside Index of Severity in Acute Pancreatitis (BISAP) and the Acute Physiology and Chronic Health Evaluation (APACHE) II tools, have good predictive capabilities for disease severity (mild, moderately severe, and severe per the revised Atlanta classification) and mortality, but no one tool works well for all forms of acute pancreatitis. Early and…
- 13top 0.9%
Prevalence and Treatment of Diabetes in China, 2013-2018
Limin Wang, Wen Hui Peng, Zhenping Zhao, Mei Zhang, Zumin Shi and 9 more
969 citationsOpen accessdoi:10.1001/jama.2021.22208OpenAlex
Show abstractHide abstract
Importance: Recent data on prevalence, awareness, treatment, and risk factors of diabetes in China is necessary for interventional efforts. Objective: To estimate trends in prevalence, awareness, treatment, and risk factors of diabetes in China based on national data. Design, Setting, and Participants: Cross-sectional nationally representative survey data collected in adults aged 18 years or older in mainland China from 170 287 participants in the 2013-2014 years and 173 642 participants in the 2018-2019 years. Exposures: Fasting plasma glucose and hemoglobin A1c levels were measured for all participants. A 2-hour oral glucose tolerance test was conducted for all participants without diagnosed diabetes. Main Outcomes and Measures: Primary outcomes were diabetes and prediabetes defined according to American Diabetes Association criteria. Secondary outcomes were awareness, treatment, and control of diabetes and prevalence of risk factors. A hemoglobin A1c level of less than 7.0% (53 mmol/mol) among treated patients with diabetes was considered adequate glycemic control. Results: In…
- 14top 0.9%
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
Brian J. Boyarsky, William A. Werbel, Robin Kimiko Avery, Aaron A.R. Tobian, Allan B. Massie and 2 more
954 citationsOpen accessdoi:10.1001/jama.2021.7489OpenAlex
Show abstractHide abstract
In contrast to immunocompetent participants in vaccine trials, 1,2 a low proportion (17%) of solid organ transplant recipients mounted a positive antibody response to the first dose of SARS-CoV-2 messenger RNA (mRNA) vaccines, with those receiving anti-metabolite maintenance immunosuppression less likely to respond. 3 In this study, we assessed antibody response after the second dose.Methods | Transplant recipients without prior polymerase chain reaction-confirmed COVID-19 were recruited from across the US to participate in this prospective cohort through a digital campaign.Those who completed the 2-dose SARS-CoV-2 mRNA vaccine series between December 16, 2020, and March 13, 2021, were included and followed up through April 13, 2021.As described previously, 3 semiquantitative antispike serologic testing was undertaken with the Roche Elecsys anti-SARS-CoV-2 S enzyme immunoassay, positive cutoff of at least 0.8 U/mL, which tests for the receptor-binding domain of the SARS-CoV-2 spike protein, 2204
- 15top 1%
The Leading Causes of Death in the US for 2020
Farida B. Ahmad, Robert N. Anderson
940 citationsOpen accessdoi:10.1001/jama.2021.5469OpenAlex
Show abstractHide abstract
This Viewpoint from the US National Center for Health Statistics reports a 2020 mortality estimate 17.7% higher than that of 2019, with leading causes of death comprising heart disease, cancer, and COVID-19.
- 16top 1%
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
Robert Gottlieb, Ajay Nirula, Peter Chen, Joseph Boscia, Barry N. Heller and 22 more
873 citationsOpen accessdoi:10.1001/jama.2021.0202OpenAlex
Show abstractHide abstract
Importance: Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19. Objective: To determine the effect of bamlanivimab monotherapy and combination therapy with bamlanivimab and etesevimab on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in mild to moderate COVID-19. Design, Setting, and Participants: The BLAZE-1 study is a randomized phase 2/3 trial at 49 US centers including ambulatory patients (N = 613) who tested positive for SARS-CoV-2 infection and had 1 or more mild to moderate symptoms. Patients who received bamlanivimab monotherapy or placebo were enrolled first (June 17-August 21, 2020) followed by patients who received bamlanivimab and etesevimab or placebo (August 22-September 3). These are the final analyses and represent findings through October 6, 2020. Interventions: Patients were randomized to receive a single infusion of bamlanivimab (700 mg [n = 101], 2800 mg [n = 107], or 7000 mg [n = 101]), the combination treatment (2800 mg of bamlanivimab and 2800 mg of…
- 17top 1.1%
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19
Leora R. Feldstein, Mark W. Tenforde, Kevin G. Friedman, Margaret M. Newhams, Erica Billig Rose and 25 more
817 citationsOpen accessdoi:10.1001/jama.2021.2091OpenAlex
Show abstractHide abstract
Importance: Refinement of criteria for multisystem inflammatory syndrome in children (MIS-C) may inform efforts to improve health outcomes. Objective: To compare clinical characteristics and outcomes of children and adolescents with MIS-C vs those with severe coronavirus disease 2019 (COVID-19). Setting, Design, and Participants: Case series of 1116 patients aged younger than 21 years hospitalized between March 15 and October 31, 2020, at 66 US hospitals in 31 states. Final date of follow-up was January 5, 2021. Patients with MIS-C had fever, inflammation, multisystem involvement, and positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcriptase-polymerase chain reaction (RT-PCR) or antibody test results or recent exposure with no alternate diagnosis. Patients with COVID-19 had positive RT-PCR test results and severe organ system involvement. Exposure: SARS-CoV-2. Main Outcomes and Measures: Presenting symptoms, organ system complications, laboratory biomarkers, interventions, and clinical outcomes. Multivariable regression was used to compute adjusted…
- 18top 1.2%
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Hui Luo, Jin Lü, Yuxian Bai, Teng Mao, Jun Wang and 25 more
813 citationsOpen accessdoi:10.1001/jama.2021.12836OpenAlex
Show abstractHide abstract
Importance: Standard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti-programmed death receptor 1 [PD-1] antibody) showed antitumor activity in previously treated advanced or metastatic esophageal squamous cell carcinoma. Objective: To evaluate the efficacy and adverse events of camrelizumab plus chemotherapy vs placebo plus chemotherapy as a first-line treatment in advanced or metastatic esophageal squamous cell carcinoma. Design, Setting, and Participants: This randomized, double-blind, placebo-controlled, multicenter, phase 3 trial (ESCORT-1st study) enrolled patients from 60 hospitals in China between December 3, 2018, and May 12, 2020 (final follow-up, October 30, 2020). A total of 751 patients were screened and 596 eligible patients with untreated advanced or metastatic esophageal squamous cell carcinoma were randomized. Interventions: Patients were randomized 1:1 to receive either camrelizumab 200 mg (n = 298) or placebo (n = 298), combined with up to 6 cycles of paclitaxel (175 mg/m2)…
- 19top 1.2%
Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke
Scott Mendelson, Shyam Prabhakaran
797 citationsdoi:10.1001/jama.2020.26867OpenAlex
Show abstractHide abstract
IMPORTANCE: Stroke is the fifth leading cause of death and a leading cause of disability in the United States, affecting nearly 800 000 individuals annually. OBSERVATIONS: Sudden neurologic dysfunction caused by focal brain ischemia with imaging evidence of acute infarction defines acute ischemic stroke (AIS), while an ischemic episode with neurologic deficits but without acute infarction defines transient ischemic attack (TIA). An estimated 7.5% to 17.4% of patients with TIA will have a stroke in the next 3 months. Patients presenting with nondisabling AIS or high-risk TIA (defined as a score ≥4 on the age, blood pressure, clinical symptoms, duration, diabetes [ABCD2] instrument; range, 0-7 [7 indicating worst stroke risk]), who do not have severe carotid stenosis or atrial fibrillation, should receive dual antiplatelet therapy with aspirin and clopidigrel within 24 hours of presentation. Subsequently, combined aspirin and clopidigrel for 3 weeks followed by single antiplatelet therapy reduces stroke risk from 7.8% to 5.2% (hazard ratio, 0.66 [95% CI, 0.56-0.77]). Patients with…
- 20top 1.3%
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
Nawal Ahmed Mohamed Al Kaabi, Yuntao Zhang, Shengli Xia, Yunkai Yang, Manaf AlQahtani and 25 more
777 citationsOpen accessdoi:10.1001/jama.2021.8565OpenAlex
Show abstractHide abstract
Importance: Although effective vaccines against COVID-19 have been developed, additional vaccines are still needed. Objective: To evaluate the efficacy and adverse events of 2 inactivated COVID-19 vaccines. Design, Setting, and Participants: Prespecified interim analysis of an ongoing randomized, double-blind, phase 3 trial in the United Arab Emirates and Bahrain among adults 18 years and older without known history of COVID-19. Study enrollment began on July 16, 2020. Data sets used for the interim analysis of efficacy and adverse events were locked on December 20, 2020, and December 31, 2020, respectively. Interventions: Participants were randomized to receive 1 of 2 inactivated vaccines developed from SARS-CoV-2 WIV04 (5 µg/dose; n = 13 459) and HB02 (4 µg/dose; n = 13 465) strains or an aluminum hydroxide (alum)-only control (n = 13 458); they received 2 intramuscular injections 21 days apart. Main Outcomes and Measures: The primary outcome was efficacy against laboratory-confirmed symptomatic COVID-19 14 days following a second vaccine dose among participants who had no…
- 21top 1.3%
Glaucoma in Adults—Screening, Diagnosis, and Management
Joshua D. Stein, Anthony P. Khawaja, Jennifer S. Weizer
734 citationsdoi:10.1001/jama.2020.21899OpenAlex
Show abstractHide abstract
Importance: Glaucoma is the most common cause of irreversible blindness worldwide. Many patients with glaucoma are asymptomatic early in the disease course. Primary care clinicians should know which patients to refer to an eye care professional for a complete eye examination to check for signs of glaucoma and to determine what systemic conditions or medications can increase a patient's risk of glaucoma. Open-angle and narrow-angle forms of glaucoma are reviewed, including a description of the pathophysiology, risk factors, screening, disease monitoring, and treatment options. Observations: Glaucoma is a chronic progressive optic neuropathy, characterized by damage to the optic nerve and retinal nerve fiber layer, that can lead to permanent loss of peripheral or central vision. Intraocular pressure is the only known modifiable risk factor. Other important risk factors include older age, nonwhite race, and a family history of glaucoma. Several systemic medical conditions and medications including corticosteroids, anticholinergics, certain antidepressants, and topiramate may predispose…
- 22top 1.4%
Racial and Ethnic Health Disparities Related to COVID-19
Leo Lopez, Louis H. Hart, Mitchell H. Katz
705 citationsdoi:10.1001/jama.2020.26443OpenAlex
Show abstractHide abstract
Racial and Ethnic Health Disparities Related to COVID-19 One of the most disturbing aspects of the coronavirus disease 2019 (COVID-19) pandemic in the US is the disproportionate harm that it has caused to historically marginalized groups.Black, Hispanic, and Asian people have substantially higher rates of infection, hospitalization, and death compared with White people. 1,2According to an analysis by the Kaiser Family Foundation and the Epic Health Research Network, based on data from the Epic health record system for 7 million Black patients, 5.1 million Hispanic patients, 1.4 million Asian patients, and 34.1 million White patients, as of July 20, 2020, the hospitalization rates and death rates per 10 000, respectively, were 24.6 and 5.6 for Black patients, 30.4 and 5.6 for Hispanic patients, 15.9 and 4.3 for Asian patients, and 7.4 and 2.3 for White patients. 2American Indian persons living in the US also have been disproportionately affected by
- 23top 1.5%
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Peré Domingo, Isabel Mur, Gracia María Mateo, María del Mar Gutiérrez and 25 more
678 citationsOpen accessdoi:10.1001/jama.2021.11330OpenAlex
Show abstractHide abstract
Importance: Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. Objective: To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes. Data Sources: Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial status or language. Additional trials were identified through contact with experts. Study Selection: Eligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom IL-6 antagonists were administered and to a group in whom neither IL-6 antagonists nor any other immunomodulators except corticosteroids were administered. Among 72 potentially eligible trials, 27 (37.5%) met study selection criteria. Data Extraction and Synthesis: In this prospective meta-analysis, risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results…
- 24top 1.5%
Screening for Colorectal Cancer
Jennifer S Lin, Leslie A Perdue, Nora Beidler Henrikson, Sarah Bean, Paula Rae Blasi
656 citationsOpen accessdoi:10.1001/jama.2021.4417OpenAlex
Show abstractHide abstract
Importance Colorectal cancer (CRC) remains a significant cause of morbidity and mortality in the US. Objective To systematically review the effectiveness, test accuracy, and harms of screening for CRC to inform the US Preventive Services Task Force. Data Sources MEDLINE, PubMed, and the Cochrane Central Register of Controlled Trials for relevant studies published from January 1, 2015, to December 4, 2019; surveillance through March 26, 2021. Study Selection English-language studies conducted in asymptomatic populations at general risk of CRC. Data Extraction and Synthesis Two reviewers independently appraised the articles and extracted relevant study data from fair- or good-quality studies. Random-effects meta-analyses were conducted. Main Outcomes and Measures Colorectal cancer incidence and mortality, test accuracy in detecting cancers or adenomas, and serious adverse events. Results The review included 33 studies (n = 10 776 276) on the effectiveness of screening, 59 (n = 3 491 045) on the test performance of screening tests, and 131 (n = 26 987 366) on the harms of screening. In…
- 25top 1.6%
Intubation Practices and Adverse Peri-intubation Events in Critically Ill Patients From 29 Countries
Vincenzo Russotto, Sheila Nainan Myatra, John Gerard Laffey, Elena Tassistro, Laura Antolini and 25 more
646 citationsOpen accessdoi:10.1001/jama.2021.1727OpenAlex
Show abstractHide abstract
Importance: Tracheal intubation is one of the most commonly performed and high-risk interventions in critically ill patients. Limited information is available on adverse peri-intubation events. Objective: To evaluate the incidence and nature of adverse peri-intubation events and to assess current practice of intubation in critically ill patients. Design, Setting, and Participants: The International Observational Study to Understand the Impact and Best Practices of Airway Management in Critically Ill Patients (INTUBE) study was an international, multicenter, prospective cohort study involving consecutive critically ill patients undergoing tracheal intubation in the intensive care units (ICUs), emergency departments, and wards, from October 1, 2018, to July 31, 2019 (August 28, 2019, was the final follow-up) in a convenience sample of 197 sites from 29 countries across 5 continents. Exposures: Tracheal intubation. Main Outcomes and Measures: The primary outcome was the incidence of major adverse peri-intubation events defined as at least 1 of the following events occurring within 30…
- 26top 1.7%
Screening for Lung Cancer With Low-Dose Computed Tomography
Daniel E Jonas, Daniel S. Reuland, Shivani M. Reddy, Max T. Nagle, Stephen D. Clark and 9 more
641 citationsOpen accessdoi:10.1001/jama.2021.0377OpenAlex
Show abstractHide abstract
Importance: Lung cancer is the leading cause of cancer-related death in the US. Objective: To review the evidence on screening for lung cancer with low-dose computed tomography (LDCT) to inform the US Preventive Services Task Force (USPSTF). Data Sources: MEDLINE, Cochrane Library, and trial registries through May 2019; references; experts; and literature surveillance through November 20, 2020. Study Selection: English-language studies of screening with LDCT, accuracy of LDCT, risk prediction models, or treatment for early-stage lung cancer. Data Extraction and Synthesis: Dual review of abstracts, full-text articles, and study quality; qualitative synthesis of findings. Data were not pooled because of heterogeneity of populations and screening protocols. Main Outcomes and Measures: Lung cancer incidence, lung cancer mortality, all-cause mortality, test accuracy, and harms. Results: This review included 223 publications. Seven randomized clinical trials (RCTs) (N = 86 486) evaluated lung cancer screening with LDCT; the National Lung Screening Trial (NLST, N = 53 454) and…
- 27top 1.7%
Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity
Mark W. Tenforde, Wesley H. Self, Katherine Adams, Manjusha Gaglani, Adit A. Ginde and 25 more
633 citationsOpen accessdoi:10.1001/jama.2021.19499OpenAlex
Show abstractHide abstract
Importance: A comprehensive understanding of the benefits of COVID-19 vaccination requires consideration of disease attenuation, determined as whether people who develop COVID-19 despite vaccination have lower disease severity than unvaccinated people. Objective: To evaluate the association between vaccination with mRNA COVID-19 vaccines-mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech)-and COVID-19 hospitalization, and, among patients hospitalized with COVID-19, the association with progression to critical disease. Design, Setting, and Participants: A US 21-site case-control analysis of 4513 adults hospitalized between March 11 and August 15, 2021, with 28-day outcome data on death and mechanical ventilation available for patients enrolled through July 14, 2021. Date of final follow-up was August 8, 2021. Exposures: COVID-19 vaccination. Main Outcomes and Measures: Associations were evaluated between prior vaccination and (1) hospitalization for COVID-19, in which case patients were those hospitalized for COVID-19 and control patients were those hospitalized for an alternative…
- 28top 1.8%
Surveillance for Adverse Events After COVID-19 mRNA Vaccination
Nicola P. Klein, Ned Lewis, Kristin Goddard, BRUCE H. FIREMAN, Ousseny Zerbo and 14 more
631 citationsOpen accessdoi:10.1001/jama.2021.15072OpenAlex
Show abstractHide abstract
Importance: Safety surveillance of vaccines against COVID-19 is critical to ensure safety, maintain trust, and inform policy. Objectives: To monitor 23 serious outcomes weekly, using comprehensive health records on a diverse population. Design, Setting, and Participants: This study represents an interim analysis of safety surveillance data from Vaccine Safety Datalink. The 10 162 227 vaccine-eligible members of 8 participating US health plans were monitored with administrative data updated weekly and supplemented with medical record review for selected outcomes from December 14, 2020, through June 26, 2021. Exposures: Receipt of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) COVID-19 vaccination, with a risk interval of 21 days for individuals after vaccine dose 1 or 2 compared with an interval of 22 to 42 days for similar individuals after vaccine dose 1 or 2. Main Outcomes and Measures: Incidence of serious outcomes, including acute myocardial infarction, Bell palsy, cerebral venous sinus thrombosis, Guillain-Barré syndrome, myocarditis/pericarditis, pulmonary embolism, stroke,…
- 29top 1.8%
Trends in Prevalence of Type 1 and Type 2 Diabetes in Children and Adolescents in the US, 2001-2017
Jean M. Lawrence, Jasmin Divers, Scott P. Isom, Sharon Saydah, Giuseppina Imperatore and 9 more
625 citationsOpen accessdoi:10.1001/jama.2021.11165OpenAlex
Show abstractHide abstract
Importance: Changes in the prevalence of youth-onset diabetes have previously been observed. Objective: To estimate changes in prevalence of type 1 and type 2 diabetes in youths in the US from 2001 to 2017. Design, Setting, and Participants: In this cross-sectional observational study, individuals younger than 20 years with physician-diagnosed diabetes were enumerated from 6 areas in the US (4 geographic areas, 1 health plan, and select American Indian reservations) for 2001, 2009, and 2017. Exposures: Calendar year. Main Outcomes and Measures: Estimated prevalence of physician-diagnosed type 1 and type 2 diabetes overall and by race and ethnicity, age, and sex. Results: Among youths 19 years or younger, 4958 of 3.35 million had type 1 diabetes in 2001, 6672 of 3.46 million had type 1 diabetes in 2009, and 7759 of 3.61 million had type 1 diabetes in 2017; among those aged 10 to 19 years, 588 of 1.73 million had type 2 diabetes in 2001, 814 of 1.85 million had type 2 diabetes in 2009, and 1230 of 1.85 million had type 2 diabetes in 2017. The estimated type 1 diabetes prevalence per…
- 30top 1.9%
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit
INSPIRATION Investigators, Saeideh Mazloomzadeh, Shiva Khaleghparast, Behshid Ghadrdoost, Mostafa Mousavizadeh and 25 more
625 citationsOpen accessdoi:10.1001/jama.2021.4152OpenAlex
Show abstractHide abstract
Importance: Thrombotic events are commonly reported in critically ill patients with COVID-19. Limited data exist to guide the intensity of antithrombotic prophylaxis. Objective: To evaluate the effects of intermediate-dose vs standard-dose prophylactic anticoagulation among patients with COVID-19 admitted to the intensive care unit (ICU). Design, Setting, and Participants: Multicenter randomized trial with a 2 × 2 factorial design performed in 10 academic centers in Iran comparing intermediate-dose vs standard-dose prophylactic anticoagulation (first hypothesis) and statin therapy vs matching placebo (second hypothesis; not reported in this article) among adult patients admitted to the ICU with COVID-19. Patients were recruited between July 29, 2020, and November 19, 2020. The final follow-up date for the 30-day primary outcome was December 19, 2020. Interventions: Intermediate-dose (enoxaparin, 1 mg/kg daily) (n = 276) vs standard prophylactic anticoagulation (enoxaparin, 40 mg daily) (n = 286), with modification according to body weight and creatinine clearance. The assigned…
- 31top 2%
Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19
Luc Morin, Laurent Savale, Tài Olivier Pham, Romain Colle, Samy Figueiredo and 20 more
602 citationsOpen accessdoi:10.1001/jama.2021.3331OpenAlex
Show abstractHide abstract
Importance: Little is known about long-term sequelae of COVID-19. Objective: To describe the consequences at 4 months in patients hospitalized for COVID-19. Design, Setting, and Participants: In a prospective uncontrolled cohort study, survivors of COVID-19 who had been hospitalized in a university hospital in France between March 1 and May 29, 2020, underwent a telephone assessment 4 months after discharge, between July 15 and September 18, 2020. Patients with relevant symptoms and all patients hospitalized in an intensive care unit (ICU) were invited for further assessment at an ambulatory care visit. Exposures: Survival of hospitalization for COVID-19. Main Outcomes and Measures: Respiratory, cognitive, and functional symptoms were assessed by telephone with the Q3PC cognitive screening questionnaire and a checklist of symptoms. At the ambulatory care visit, patients underwent pulmonary function tests, lung computed tomographic scan, psychometric and cognitive tests (including the 36-Item Short-Form Health Survey and 20-item Multidimensional Fatigue Inventory), and, for patients…
- 32top 2%
Genetic Variants of SARS-CoV-2—What Do They Mean?
Adam S. Lauring, Emma B. Hodcroft
601 citationsOpen access (CC-BY)doi:10.1001/jama.2020.27124OpenAlex
Show abstractHide abstract
This Viewpoint discusses emerging genetic variants of SARS-CoV-2, including new “UK” and “mink” variants and the significance of the new variants to coronavirus transmissibility, spread, virulence, and efforts to vaccinate the population against COVID-19.
- 33top 2.1%
Trends in Prevalence of Diabetes and Control of Risk Factors in Diabetes Among US Adults, 1999-2018
Li Wang, Xiaoguang Li, Zhaoxin Wang, Michael P. Bancks, Mercedes R. Carnethon and 4 more
573 citationsOpen accessdoi:10.1001/jama.2021.9883OpenAlex
Show abstractHide abstract
IMPORTANCE: Understanding population-wide trends in prevalence and control of diabetes is critical to planning public health approaches for prevention and management of the disease. OBJECTIVE: To determine trends in prevalence of diabetes and control of risk factors in diabetes among US adults between 1999-2000 and 2017-2018. DESIGN, SETTING, AND PARTICIPANTS: Ten cycles of cross-sectional National Health and Nutrition Examination Survey (NHANES) data between 1999-2000 and 2017-2018 were included. The study samples were weighted to be representative of the noninstitutionalized civilian resident US population. Adults aged 18 years or older were included, except pregnant women. EXPOSURES: Survey cycle. MAIN OUTCOMES AND MEASURES: Diabetes was defined by self-report of diabetes diagnosis, fasting plasma glucose level of 126 mg/dL or more, or hemoglobin A1c (HbA1c) level of 6.5% or more. Three risk factor control goals were individualized HbA1c targets, blood pressure less than 130/80 mm Hg, and low-density lipoprotein cholesterol level less than 100 mg/dL. Prevalence of diabetes and…
- 34top 2.1%
Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017
Ashley H. Hirai, Jean Y. Ko, Pamela L Owens, Carol Stocks, Stephen W. Patrick
571 citationsOpen accessdoi:10.1001/jama.2020.24991OpenAlex
Show abstractHide abstract
Importance: Substantial increases in both neonatal abstinence syndrome (NAS) and maternal opioid use disorder have been observed through 2014. Objective: To examine national and state variation in NAS and maternal opioid-related diagnoses (MOD) rates in 2017 and to describe national and state changes since 2010 in the US, which included expanded MOD codes (opioid use disorder plus long-term and unspecified use) implemented in International Classification of Disease, 10th Revision, Clinical Modification. Design, Setting, and Participants: Repeated cross-sectional analysis of the 2010 to 2017 Healthcare Cost and Utilization Project's National Inpatient Sample and State Inpatient Databases, an all-payer compendium of hospital discharge records from community nonrehabilitation hospitals in 47 states and the District of Columbia. Exposures: State and year. Main Outcomes and Measures: NAS rate per 1000 birth hospitalizations and MOD rate per 1000 delivery hospitalizations. Results: In 2017, there were 751 037 birth hospitalizations and 748 239 delivery hospitalizations in the national…
- 35top 2.2%
A Guideline for Reporting Mediation Analyses of Randomized Trials and Observational Studies
Hopin Lee, Aidan Gregory Cashin, Sarah E Lamb, Sally Hopewell, Stijn Vansteelandt and 17 more
555 citationsOpen access (CC-BY-NC-ND)doi:10.1001/jama.2021.14075OpenAlex
Show abstractHide abstract
Importance: Mediation analyses of randomized trials and observational studies can generate evidence about the mechanisms by which interventions and exposures may influence health outcomes. Publications of mediation analyses are increasing, but the quality of their reporting is suboptimal. Objective: To develop international, consensus-based guidance for the reporting of mediation analyses of randomized trials and observational studies (A Guideline for Reporting Mediation Analyses; AGReMA). Design, Setting, and Participants: The AGReMA statement was developed using the Enhancing Quality and Transparency of Health Research (EQUATOR) methodological framework for developing reporting guidelines. The guideline development process included (1) an overview of systematic reviews to assess the need for a reporting guideline; (2) review of systematic reviews of relevant evidence on reporting mediation analyses; (3) conducting a Delphi survey with panel members that included methodologists, statisticians, clinical trialists, epidemiologists, psychologists, applied clinical researchers,…
- 36top 2.3%
Effect of Mechanical Thrombectomy Without vs With Intravenous Thrombolysis on Functional Outcome Among Patients With Acute Ischemic Stroke
Kentaro Suzuki, Yuji Matsumaru, Masataka Takeuchi, Masafumi Morimoto, Ryuzaburo Kanazawa and 25 more
549 citationsOpen accessdoi:10.1001/jama.2020.23522OpenAlex
Show abstractHide abstract
IMPORTANCE: Whether intravenous thrombolysis is needed in combination with mechanical thrombectomy in patients with acute large vessel occlusion stroke is unclear. OBJECTIVE: To examine whether mechanical thrombectomy alone is noninferior to combined intravenous thrombolysis plus mechanical thrombectomy for favorable poststroke outcome. DESIGN, SETTING, AND PARTICIPANTS: Investigator-initiated, multicenter, randomized, open-label, noninferiority clinical trial in 204 patients with acute ischemic stroke due to large vessel occlusion enrolled at 23 hospital networks in Japan from January 1, 2017, to July 31, 2019, with final follow-up on October 31, 2019. INTERVENTIONS: Patients were randomly assigned to mechanical thrombectomy alone (n = 101) or combined intravenous thrombolysis (alteplase at a 0.6-mg/kg dose) plus mechanical thrombectomy (n = 103). MAIN OUTCOMES AND MEASURES: The primary efficacy end point was a favorable outcome defined as a modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]) of 0 to 2 at 90 days, with a noninferiority margin odds ratio of 0.74,…
- 37top 2.3%
Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin
Thomas W. Martens, Roy W. Beck, Ryan J. Bailey, Katrina J. Ruedy, Peter M. Calhoun and 25 more
543 citationsOpen accessdoi:10.1001/jama.2021.7444OpenAlex
Show abstractHide abstract
Importance: Continuous glucose monitoring (CGM) has been shown to be beneficial for adults with type 2 diabetes using intensive insulin therapy, but its use in type 2 diabetes treated with basal insulin without prandial insulin has not been well studied. Objective: To determine the effectiveness of CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin in primary care practices. Design, Setting, and Participants: This randomized clinical trial was conducted at 15 centers in the US (enrollment from July 30, 2018, to October 30, 2019; follow-up completed July 7, 2020) and included adults with type 2 diabetes receiving their diabetes care from a primary care clinician and treated with 1 or 2 daily injections of long- or intermediate-acting basal insulin without prandial insulin, with or without noninsulin glucose-lowering medications. Interventions: Random assignment 2:1 to CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59). Main Outcomes and Measures: The primary outcome was hemoglobin A1c (HbA1c) level at 8 months. Key secondary…
- 38top 2.4%
Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves
Caroline Maslo, Richard Friedland, Mande Toubkin, Anchen Laubscher, Teshlin Akaloo and 1 more
534 citationsOpen accessdoi:10.1001/jama.2021.24868OpenAlex
Show abstractHide abstract
On November 24, 2021, a SARS-CoV-2 variant of concern, Omicron (B.1.1.529),was identified in South Africa as responsible for a fourth wave of COVID-19.1,2 The high number of spike mutations has raised concerns about its ability to evade vaccine and spread.3,4 We assessed hospitalized patients with a positive SARS-CoV-2 test result during the fourth wave compared with previous waves.Methods | Netcare is a private health care group consisting of 49 acute care hospitals (>10 000 beds) across South Africa.South Africa has experienced 3 COVID-19 waves: (1) June to August 2020 (ancestral variant), (2) November 2020 to January 2021 (Beta), and (3) May to September 2021 (Delta).Cases again started to increase beginning November 15, 2021, coinciding with the identification of Omicron; as of December 7, 26% community positivity rates were reached.We identified the period when 26% positivity rates were reached in the previous waves (wave 1: June 14 to July 6, 2020; wave 2: December 1-23, 2020; wave 3: June 1-23, 2021) and compared them with the fourth wave (November 15 to December 7, 2021).For…
- 39top 2.5%
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021
Isaac See, John R. Su, Allison Lale, Emily Jane Woo, Alice Y. Guh and 19 more
533 citationsOpen accessdoi:10.1001/jama.2021.7517OpenAlex
Show abstractHide abstract
Importance: Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed. In the US, the Ad26.COV2.S COVID-19 vaccine (Janssen/Johnson & Johnson), which uses a human adenoviral vector, received Emergency Use Authorization (EUA) on February 27, 2021. By April 12, 2021, approximately 7 million Ad26.COV2.S vaccine doses had been given in the US, and 6 cases of CVST with thrombocytopenia had been identified among the recipients, resulting in a temporary national pause in vaccination with this product on April 13, 2021. Objective: To describe reports of CVST with thrombocytopenia following Ad26.COV2.S vaccine receipt. Design, Setting, and Participants: Case series of 12 US patients with CVST and thrombocytopenia following use of Ad26.COV2.S vaccine under EUA reported to the Vaccine Adverse Event Reporting System (VAERS) from…
- 40top 2.5%
Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke
Wenjie Zi, Zhongming Qiu, Fengli Li, Hongfei Sang, Deping Wu and 25 more
532 citationsOpen accessdoi:10.1001/jama.2020.23523OpenAlex
Show abstractHide abstract
Importance: For patients with large vessel occlusion strokes, it is unknown whether endovascular treatment alone compared with intravenous thrombolysis plus endovascular treatment (standard treatment) can achieve similar functional outcomes. Objective: To investigate whether endovascular thrombectomy alone is noninferior to intravenous alteplase followed by endovascular thrombectomy for achieving functional independence at 90 days among patients with large vessel occlusion stroke. Design, Setting, and Participants: Multicenter, randomized, noninferiority trial conducted at 33 stroke centers in China. Patients (n = 234) were 18 years or older with proximal anterior circulation intracranial occlusion strokes within 4.5 hours from symptoms onset and eligible for intravenous thrombolysis. Enrollment took place from May 20, 2018, to May 2, 2020. Patients were enrolled and followed up for 90 days (final follow-up was July 22, 2020). Interventions: A total of 116 patients were randomized to the endovascular thrombectomy alone group and 118 patients to combined intravenous thrombolysis and…
- 41top 2.6%
Effect of a Single High Dose of Vitamin D 3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19
Igor Hisashi Murai, Alan Lins Fernandes, Lucas Peixoto Sales, Ana Jéssica Pinto, Karla Fabiana Goessler and 12 more
528 citationsOpen accessdoi:10.1001/jama.2020.26848OpenAlex
Show abstractHide abstract
Importance: The efficacy of vitamin D3 supplementation in coronavirus disease 2019 (COVID-19) remains unclear. Objective: To investigate the effect of a single high dose of vitamin D3 on hospital length of stay in patients with COVID-19. Design, Setting, and Participants: This was a multicenter, double-blind, randomized, placebo-controlled trial conducted in 2 sites in Sao Paulo, Brazil. The study included 240 hospitalized patients with COVID-19 who were moderately to severely ill at the time of enrollment from June 2, 2020, to August 27, 2020. The final follow-up was on October 7, 2020. Interventions: Patients were randomly assigned to receive a single oral dose of 200 000 IU of vitamin D3 (n = 120) or placebo (n = 120). Main Outcomes and Measures: The primary outcome was length of stay, defined as the time from the date of randomization to hospital discharge. Prespecified secondary outcomes included mortality during hospitalization; the number of patients admitted to the intensive care unit; the number of patients who required mechanical ventilation and the duration of mechanical…
- 42top 2.6%
Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons
US Preventive Services Task Force, Alex H. Krist, Karina W. Davidson, Carol M. Mangione, Michael J. Barry and 12 more
511 citationsdoi:10.1001/jama.2020.25019OpenAlex
Show abstractHide abstract
IMPORTANCE: Tobacco use is the leading preventable cause of disease, disability, and death in the US. In 2014, it was estimated that 480 000 deaths annually are attributed to cigarette smoking, including second hand smoke exposure. Smoking during pregnancy can increase the risk of numerous adverse pregnancy outcomes (eg, miscarriage and congenital anomalies) and complications in the offspring (including sudden infant death syndrome and impaired lung function in childhood). In 2019, an estimated 50.6 million US adults (20.8% of the adult population) used tobacco; 14.0% of the US adult population currently smoked cigarettes and 4.5% of the adult population used electronic cigarettes (e-cigarettes). Among pregnant US women who gave birth in 2016, 7.2% reported smoking cigarettes while pregnant. OBJECTIVE: To update its 2015 recommendation, the USPSTF commissioned a review to evaluate the benefits and harms of primary care interventions on tobacco use cessation in adults, including pregnant persons. POPULATION: This recommendation statement applies to adults 18 years or older, including…
- 43top 2.7%
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
Brian J. Boyarsky, William A. Werbel, Robin Kimiko Avery, Aaron A.R. Tobian, Allan B. Massie and 2 more
507 citationsOpen accessdoi:10.1001/jama.2021.4385OpenAlex
Show abstractHide abstract
This study quantifies antispike protein antibody responses to first-dose messenger RNA (mRNA) COVID-19 vaccines in solid organ transplant recipients to better understand the immunogenicity of the vaccines in immunocompromised individuals.
- 44top 2.8%
Screening for Prediabetes and Type 2 Diabetes
US Preventive Services Task Force, Karina W. Davidson, Michael J. Barry, Carol M. Mangione, Michael D. Cabana and 14 more
480 citationsOpen accessdoi:10.1001/jama.2021.12531OpenAlex
Show abstractHide abstract
Importance: An estimated 13% of all US adults (18 years or older) have diabetes, and 34.5% meet criteria for prediabetes. The prevalences of prediabetes and diabetes are higher in older adults. Estimates of the risk of progression from prediabetes to diabetes vary widely, perhaps because of differences in the definition of prediabetes or the heterogeneity of prediabetes. Diabetes is the leading cause of kidney failure and new cases of blindness among adults in the US. It is also associated with increased risks of cardiovascular disease, nonalcoholic fatty liver disease, and nonalcoholic steatohepatitis and was estimated to be the seventh leading cause of death in the US in 2017. Screening asymptomatic adults for prediabetes and type 2 diabetes may allow earlier detection, diagnosis, and treatment, with the ultimate goal of improving health outcomes. Objective: To update its 2015 recommendation, the USPSTF commissioned a systematic review to evaluate screening for prediabetes and type 2 diabetes in asymptomatic, nonpregnant adults and preventive interventions for those with…
- 45top 2.8%
Effect of Helmet Noninvasive Ventilation vs High-Flow Nasal Oxygen on Days Free of Respiratory Support in Patients With COVID-19 and Moderate to Severe Hypoxemic Respiratory Failure
Domenico Luca Grieco, Luca Salvatore Menga, Melania Cesarano, Tommaso Rosà, Savino Spadaro and 25 more
476 citationsOpen accessdoi:10.1001/jama.2021.4682OpenAlex
Show abstractHide abstract
Importance: High-flow nasal oxygen is recommended as initial treatment for acute hypoxemic respiratory failure and is widely applied in patients with COVID-19. Objective: To assess whether helmet noninvasive ventilation can increase the days free of respiratory support in patients with COVID-19 compared with high-flow nasal oxygen alone. Design, Setting, and Participants: Multicenter randomized clinical trial in 4 intensive care units (ICUs) in Italy between October and December 2020, end of follow-up February 11, 2021, including 109 patients with COVID-19 and moderate to severe hypoxemic respiratory failure (ratio of partial pressure of arterial oxygen to fraction of inspired oxygen ≤200). Interventions: Participants were randomly assigned to receive continuous treatment with helmet noninvasive ventilation (positive end-expiratory pressure, 10-12 cm H2O; pressure support, 10-12 cm H2O) for at least 48 hours eventually followed by high-flow nasal oxygen (n = 54) or high-flow oxygen alone (60 L/min) (n = 55). Main Outcomes and Measures: The primary outcome was the number of days free…
- 46top 2.9%
Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US—December 14, 2020-January 18, 2021
Tom T. Shimabukuro, Matthew Cole, John R. Su
475 citationsOpen accessdoi:10.1001/jama.2021.1967OpenAlex
Show abstractHide abstract
This JAMA Insights review provides clinical details of anaphylactic reactions reported to and verified by the CDC in the first month of use of the Pfizer-BioNTech and Moderna COVID-19 vaccines in the US, December 14, 2020-January 18, 2021.
- 47top 2.9%
What’s Wrong With Advance Care Planning?
R. Sean Morrison, Diane E. Meier, Robert M. Arnold
448 citationsOpen accessdoi:10.1001/jama.2021.16430OpenAlex
- 48top 3%
Immortal Time Bias in Observational Studies
Kabir Yadav, Roger J. Lewis
447 citationsdoi:10.1001/jama.2020.9151OpenAlex
- 49top 3.1%
Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis
Kim Louise Bennell, Kade L. Paterson, Ben R. Metcalf, Vicky Duong, Jillian Peta Eyles and 12 more
442 citationsOpen accessdoi:10.1001/jama.2021.19415OpenAlex
Show abstractHide abstract
Importance: Most clinical guidelines do not recommend platelet-rich plasma (PRP) for knee osteoarthritis (OA) because of lack of high-quality evidence on efficacy for symptoms and joint structure, but the guidelines emphasize the need for rigorous studies. Despite this, use of PRP in knee OA is increasing. Objective: To evaluate the effects of intra-articular PRP injections on symptoms and joint structure in patients with symptomatic mild to moderate radiographic medial knee OA. Design, Setting, and Participants: This randomized, 2-group, placebo-controlled, participant-, injector-, and assessor-blinded clinical trial enrolled community-based participants (n = 288) aged 50 years or older with symptomatic medial knee OA (Kellgren and Lawrence grade 2 or 3) in Sydney and Melbourne, Australia, from August 24, 2017, to July 5, 2019. The 12-month follow-up was completed on July 22, 2020. Interventions: Interventions involved 3 intra-articular injections at weekly intervals of either leukocyte-poor PRP using a commercially available product (n = 144 participants) or saline placebo (n =…
- 50top 3.1%
Cardiogenic Shock After Acute Myocardial Infarction
Marc D. Samsky, David A. Morrow, Alastair G. Proudfoot, Judith S. Hochman, Hölger Thiele and 1 more
437 citationsOpen accessdoi:10.1001/jama.2021.18323OpenAlex
Show abstractHide abstract
IMPORTANCE: Cardiogenic shock affects between 40 000 and 50 000 people in the US per year and is the leading cause of in-hospital mortality following acute myocardial infarction. OBSERVATIONS: Thirty-day mortality for patients with cardiogenic shock due to myocardial infarction is approximately 40%, and 1-year mortality approaches 50%. Immediate revascularization of the infarct-related coronary artery remains the only treatment for cardiogenic shock associated with acute myocardial infarction supported by randomized clinical trials. The Percutaneous Coronary Intervention Strategies with Acute Myocardial Infarction and Cardiogenic Shock (CULPRIT-SHOCK) clinical trial demonstrated a reduction in the primary outcome of 30-day death or kidney replacement therapy; 158 of 344 patients (45.9%) in the culprit lesion revascularization-only group compared with 189 of 341 patients (55.4%) in the multivessel percutaneous coronary intervention group (relative risk, 0.83 [95% CI, 0.71-0.96]; P = .01). Despite a lack of randomized trials demonstrating benefit, percutaneous mechanical circulatory…
How to read this list
The cohort is every article, review and book chapter OpenAlex attributes to JAMA with publication year 2021, excluding retracted works and paratext such as editorials and errata. The top 50 by citation count are listed; the percentile is the rank divided by the cohort size. 48 of the 50 entries have an abstract in OpenAlex. Counts were read on 29 October 2026 and will not be updated on this page, so a quoted rank stays verifiable. Full rules on the methodology page.
Other journals, same idea
Work with these 25 papers in Kahubi
- The papers land in your library with their DOIs
- Ask anything across all of them, with citations
- Draft a literature review from the same sources
Free plan, no card. Your files stay private unless you share them.
Reading several of these?
Kahubi reads papers with you, keeps every citation traceable and drafts with sources you can check. Free plan, no card.